S.Korea's Kainos Medicine exports AIDS treatment technology to China

South Korean new drug developer Kainos Medicine Inc. announced on Friday that it had signed a technology transfer agreement with Chinese pharmaceutical company Jiangsu Aidea Pharmaceutical Co. for its AIDS treatment drug, KM-023, targeting global regions except for Korea.

Under this agreement, Jiangsu Aidea will have exclusive rights to develop and commercialize KM-023 in regions outside Korea. Previously, Jiangsu Aidea acquired the rights to KM-023 in China in 2014.

Kainos will receive a 45% royalty on the gross profits from sales in countries where they hold patents. If KM-023 is released in countries where Kainos does not hold patents but receives regulatory approval from the European Medicines Agency (EMA), it will receive 10% of the sales revenue.

Kainos Medicine also stated that even after the patent expires in Europe, it will receive a 10% royalty for a certain period of time if it receives exclusive data rights by obtaining product approval from the EMA.

Write to Jeong Min Nam at peux@hankyung.com